Cancer Cell Research (Online ISSN: 2161-2609)

by  Yuanli Guo, Shifeng Dai, Weifeng Wei

Cancer Cell Research 2018 5(17) 408-411; published online 25 January 2018

Abstract: To study the epithelial mesenchymal transition markers of E-cadherin and Vimentin expression in endometrial cancer patients with chemotherapy drug resistance. And then analyze relations with HER2 and epithelial mesenchymal transition. 75 cases of Endometrial carcinoma patients were collect in our hospital, which of 32 cases of patients were diagnosed by the clinical and pathological for adjuvant chemotherapy drug resistance. All patients were undergone surgical removal of the lesions and detected with pathologic examination. The epithelial mesenchymal transition markers of E-cadherin and Vimentin expression were detected by immunohistochemical. Level of Vimentin expression in resistant group were increased, and E-cadherin expression decreased (P<0.05). In 43 cases with HER2 positive, Vimentin expression level increased, E-cadherin decreased too, when compared with HER2 negative expression group, they had differences statistically significant (P<0.05). Spreamen correlation analysis showed that HER2 was negatively correlated with E-cadherin protein expression (R=0.336, P=0.336), and was positively related with Vimentin expression (R=0.587, P=0.587). In endometrial cancer patients with chemotherapy drug resistance, especially HER2 positive patients, it possible raise the expression of Vimentin and downgrade E-cadherin express to promote epithelial-mesenchymal transition, and received the occurrence of drug resistance. But the specific molecular biological mechanism still needs further research.

by  Yong Tao, Guangen Yang, Jianming Qiu, Dong Wang, Hongtao Wang, Chao Fu

Cancer Cell Research 2018 5(17) 412-419; published online 26 January 2018

Abstract: Increasing evidences suggest that cancer-triggered inflammation was associated with survival prognosis from colorectal cancer (CRC). However, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) predict prognosis in adjuvant chemotherapy are rarely investigated. A retrospective clinical data and baseline laboratory parameters of 215 CRC patients with adjuvant chemotherapy were collected between January 2007 to January 2012. The clinicopathological characteristics were compared. Statistical analysis was used to identify the predictive value of NLR and PLR associated with survival prognosis. The optimal prechemotherapy NLR and PLR cut-off value was 2.32 and 178 by the ROC analysis. Elevated NLR (≥2.32) and PLR (≥178) were obviously correlated with poor OS and RFS (all P<0.05). Moreover, statistical analysis concluded elevated NLR (≥2.32) as an prognostic factor for poor OS (P=0.005, RR 1.942, 95%CI 1.253-3.051), RFS (P=0.010, RR 1.492, 95%CI 0.458-3.281) while elevated PLR (≥178) was for poor OS (P=0.020, RR 1.585, 95%CI1.072-2.527). Thus, prechemotherapy increased NLR and PLR may server as useful clinical prognostic predictors in CRC patients with adjuvant chemotherapy, which were associated with poor prognosis.

by  Fei Xu, Leina Ma, Lingxin Feng, Yinjie Wu, Xiaoyan Xu, Zhuang Yu

Cancer Cell Research 2018 5(17) 420-426; published online 30 January 2018

Abstract: Recent studies have shown that microRNA-21 (miR-21) may act as a prognostic biomarker in non-small cell lung cancer (NSCLC). However, the available results remain controversial. Therefore, we performed a meta-analysis to identify the prognostic role of miR-21 in NSCLC. Eligible published studies were identified and assessed for quality through several search strategies. Data were extracted from each study to investigate the association between miR-21 and survival in NSCLC patients. With respect to survival outcomes, the hazard ratio (HR) with 95% confidence intervals was utilized to calculate pooled effect size. A total of nine articles involving 1639 cases were identified in this meta-analysis. The pooled HR suggested that a high miR-21 expression can significantly predict worse NSCLC survival (HR=2.29, 95%CI: 1.58-3.33 P<0.0001). Moreover, elevated miR-21 level was significantly correlation with lowered overall survival (OS) in the Asian group (HR=2.88 95%CI: 1.64-5.08 P<0.00001) than Caucasian cohort (HR=1.57 95%CI: 0.68-3.65 P=0.0002). Furthermore, subgroup analysis suggested that circulating miR-21 had a prognostic value in patients with NSCLC (HR=2.49 95%CI: 1.85-3.35 P<0.00001). This meta-analysis provides evidence that miR-21 can predict unfavorable prognosis in NSCLC.

by  Zhenjie Yang, Jing Yang, Peng Li, Chuandong Sun

Cancer Cell Research 2018 5(17) 427-431; published online 30 January 2018

Abstract: To explore apoptosis sensitivity effect of the different concentration of adriamycin (ADM) combined with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene on human hepatocellular carcinoma (HCC) SMMC-7721 cells, and further explore the mechanism of apoptosis of SMMC-7721 cells. TRAIL lentivirus infected SMMC-7721 cells, and the efficiency of infection was observed by fluorescence microscopy. Expression of TRAIL gene was detected by qRT-PCR. The effect of different concentration of ADM combined with TRAIL gene on the proliferation of SMMC-7721 cells was detected by CCK8. The apoptosis of cell was detected by Hoechst 33258 and Western blot. The results of qRT-PCR showed the expression of SMMC-7721-TRAIL increased significantly (P< 0.001), and the expression of TRAIL gene in the TRAIL-NC was basically no difference (P>0.05). The results of CCK8 showed that inhibition rates of cell treated with ADM combined with TRAIL gene for 24h and 48h, compared with the control group, F=24.16, p=0.01 and F=89.43, P<0.001. Hoechst 33258 showed that ADM combined with TRAIL gene could cause chromatin condensation and nuclear fragmentation. Further studies show that the expression of DR4 and DR5 protein in cells detected by western blot was up-expression, compared with the control group, F=43.72, P=0.0144 and F=12.12, P=0.0024. ADM could increase the sensitivity of TRAIL gene and promote the apoptosis of SMMC-7721 cells, which indicates that chemotherapy drugs have broad application prospects in tumor gene therapy.

by  Chuan Li, Ronghua Yang, Kaihua Tian, Wenjie Jiao

Cancer Cell Research 2018 5(17) 431-434; published online 15 February 2018

Abstract: Numerous studies suggest the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) including gifitinib, erlotinib and icotinib have fairly effective anti-tumor activity in local advanced Non-Small Cell Lung Cancer (NSCLC) with mutation or amplification of EGFR gene. We reported two cases of surgical resection after clinical stage downgrading by taking orally icotinib preoperatively in patients with local advanced NSCLC. Both of the patients had mediastinal lymphadenopathy with high FDG uptake and were staged as clinical IIIa. After the induction treatment of icotinib, they both acquired tumor regression and underwent resection of residual disease. The induction treatment did not increase after operative complications in the two patients. We believe that it is significant and necessary to discuss the role of preoperative neoadjuvant therapy of icotinib in patients with local advanced non-small cell lung cancer harboring EGFR gene mutation in future clinical trials.